Redefining the Patient-Physician Journey with AI | Trust & Interoperability | Dr. Barry Chaiken

Send us Fan Mail

AI governance, interoperability, and healthcare AI strategy for 2050 — Dr. Barry Chaiken on why powerful AI tools require governance before deployment.

AI in healthcare is powerful, and powerful tools require governance before they require deployment. Dr. Barry Chaiken, a physician leader with more than 25 years in clinical transformation, health IT, and public health, continues his conversation with host Christopher Hutchins on what responsible AI adoption actually looks like at the point of care. Part 2 moves from theory to the questions leaders need to answer before any AI touches a patient.

What We Cover

• Why AI deployment should start with a clearly defined goal and iterate in small cycles of execute, learn, and adjust rather than launching at scale from day one.
• Algorithmic bias and the diverging regulatory approaches between the United States and the European Union, including why deep fakes influencing roughly 160 elections worldwide is a governance problem healthcare cannot ignore.
• Healthcare interoperability through the lens of global ATM networks, and why EMR vendors have a responsibility to make patient data portable.
• A 2050 vision for AI-accelerated drug development through AlphaFold-style protein folding research, clinical trials conducted in silico using digital twins, and personalized patient engagement that accounts for real-world constraints.
• How to read vendor claims skeptically, including Dr. Chaiken's observation that even Sam Altman does not fully understand how AI works.

Key Takeaways

Humans should control AI; AI should never control humans. Without human knowledge, experience, ethics, and values directing AI, models hallucinate and cause harm. With those qualities guiding them, AI can do meaningful work.

Interoperability is a patient-rights issue, not an IT issue. The data belongs to the patient. EMR companies that make portability difficult are defending a business model at the expense of the patient relationship.

Digital twins and in silico trials will redefine drug development. By 2050, personalized simulation will compress timelines that currently take more than a decade. That shift is already beginning, and healthcare leaders should be building the data infrastructure that supports it.

Frameworks & Tools Mentioned

• DocsNetwork (consultancy for clinical innovation and patient safety)
• HIMSS governance frameworks
• AlphaFold protein folding research
• Digital twin and in silico trial architectures
• US vs EU algorithmic bias regulatory comparison

About Dr. Barry Chaiken

Dr. Barry Chaiken is a physician leader with more than 25 years of experience in clinical transformation, health IT, and public health. He has served as chief medical officer for multiple health tech companies, advised the federal government on pandemic preparedness, and is a past board chair of HIMSS. He is the founder of DocsNetwork, a consultancy focused on clinical innovation and patient safety, and author of Future Healthcare 2050.

Related Resources

Related episodes:

• How AI Redefines the Patient-Physician Journey (Part 1)
• Balancing Human Judgment and Clinical Trust in Healthcare
• The Scary Truth About AI in the ER and Why Clinical Judgment Still Wins

Related topic: Clinical AI and Patient Care

Related article: 

Support the show

About The Signal Room: The Signal Room is a podcast and communications platform exploring leadership, ethics, and innovation in healthcare and artificial intelligence. Hosted by Christopher Hutchins, Founder and CEO of Hutchins Data Strategy Consultants. Leadership, ethics, and innovation, amplified.

Website: https://www.hutchinsdatastrategy.com 

LinkedIn: https://www.linkedin.com/in/chutchins-healthcare/ 

YouTube: https://www.youtube.com/@ChrisHutchinsAi

Book Chris to speak:  https://www.chrisjhutchins.com